Micael Hardy

Micael Hardy is a Senior Lecturer at Aix-Marseille University, affiliated with the Structure and Reactivity of Paramagnetic Species (SREP) Team. His research centers on developing probes for superoxide radical detection in biological systems and designing mitochondria-targeted agents for anticancer therapies. Utilizing spin trapping techniques and oxidative stress analysis, he bridges chemical biology and translational medicine.

Hardy's work in oxidative stress focuses on nitrones and radical traps for sensitive superoxide detection, with applications in understanding redox signaling. In cancer therapeutics, he pioneers mitochondria-targeted compounds like mito-honokiol and mito-atovaquone to disrupt tumor metabolism, inhibit proliferation, and modulate immune responses. His research spans prostate, lung, and breast cancers alongside Parkinson's disease interventions.

Recent publications (2023-2025) reveal a strategic emphasis on metabolic modulation of tumors through OXPHOS inhibition, hypoxia alleviation, and immune microenvironment reshaping. Key innovations include honokiol-short-chain fatty acid derivatives for Parkinson's therapy and PEGylated mito-atovaquone as hypoxia modifiers, demonstrating cross-disciplinary impact in oncology and neuropharmacology.

Information regarding Micael Hardy's advised students, grant funding, and scientific awards was not provided in the source material.

As a core member of the SREP Team, Hardy contributes to projects spanning bioactive molecule design, chemical reactivity of radical species, and in vitro/in vivo validation. The team integrates organic synthesis, biochemical modeling, and advanced spectroscopic techniques to develop therapeutic agents targeting mitochondrial dysfunction in cancer and neurodegeneration.